- Depomed (DEPO) downgraded to Neutral from Buy with a $17 (0% upside) price target by Mizuho Securities.
- Invitae (NYSE:NVTA) upgraded to Buy from Hold with an $11 (20% upside) price target by Benchmark.
- Zosano Pharma (NASDAQ:ZSAN) price target raised to $3.25 (91% upside) from $2.00 by Roth Capital.
- HealthSouth (HLS) initiated with Buy rating and $48 (18% upside) price target by Craig-Hallum.
- Dentsply Sirona (NASDAQ:XRAY) upgraded to Buy with a $70 (19% upside) price target by Stifel Nicolaus.
- Valeant Pharmaceuticals (VRX) price target reduced to $22 (47% upside) by both RBC and Royal Bank of Canada.